Prescription Medicines
KD Fanitine Tab. 20mg
- Product Category
- Peptic ulcer treatment
- Active Ingredients
- Famotidine
- Appearance
- Light green, round, film-coated tablets
- Reimbursement Code
- 648104390
01 / 02
1. Composition and Strength : 1 tablet
- Active ingredient: Famotidine (KP) --- 20mg
- Additives (tar color aluminum lake): Blue No. 1, Yellow No. 203
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, corn starch, calcium hydrogen phosphate hydrate, sodium starch glycolate, purified water, Tabshield Green (91G941)
2. Effectiveness
1. Main effect
Gastric/duodenal ulcer, anastomotic ulcer, upper digestive tract bleeding (due to peptic ulcer, acute stress ulcer, hemorrhagic gastritis), reflux esophagitis, Zollinger-Ellison syndrome,
Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) of the following diseases: acute gastritis, acute exacerbation of chronic gastritis
3. Dosage and dosage
1. Gastric/duodenal ulcer, anastomotic ulcer, upper digestive tract bleeding (due to peptic ulcer, acute stress ulcer, bleeding ulcer), reflux esophagitis, Zollinger-Ellison syndrome
Adults: As famotidine, take 20 mg orally twice a day (after breakfast, dinner, or at bedtime) or 40 mg once a day (at bedtime).
In the case of upper digestive tract bleeding, treatment is usually initiated with injections and then switched to oral administration after oral administration becomes possible.
2. Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) of the following diseases: acute gastritis, acute exacerbation of chronic gastritis
Adults: As famotidine, take 10 mg orally twice a day (after breakfast, dinner, or at bedtime) or 20 mg once a day (at bedtime).
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to the components of this drug or other H₂ receptor antagonists
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to drugs
2) Patients with renal impairment (reduce the dose or use at intervals as blood levels persist)
3) Patients with heart disease (may cause side effects in the cardiovascular system)
4) Patients with liver failure (symptoms may worsen)
5) Elderly people
3. Side effects
1) Serious side effects
① Shock and hypersensitivity (less than 0.1%): Shock and hypersensitivity (anaphylaxis, difficulty breathing, flushing of the body, angioedema (facial edema, pharyngeal edema, etc.), urticaria, etc.) may occur, so observe thoroughly and if abnormalities are recognized, stop administration and take appropriate measures.
② Pancytopenia, agranulocytosis, aplastic anemia, hemolytic anemia (frequency unknown), thrombocytopenia (less than 0.1%): Pancytopenia, agranulocytosis, aplastic anemia, hemolytic anemia, and thrombocytopenia (early symptoms include general malaise, asthenia, subcutaneous and submucosal hemorrhage, fever, etc.) may occur, so conduct blood tests regularly, and if abnormalities are recognized, Stop administration and take appropriate measures.
③ Stevens-Johnson syndrome (cutaneous mucous membrane ocular syndrome), Riell syndrome (toxic epidermal necrolysis) (frequency unknown): Stevens-Johnson syndrome (cutaneous mucous membrane ocular syndrome) and Riel syndrome (toxic epidermal necrolysis) may occur, so observe thoroughly. If these symptoms appear, stop administration and take appropriate measures.
④ Liver dysfunction, jaundice (frequency unknown): Increases in AST (GOT), ALT (GPT), etc. and jaundice may occur, so observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
⑤ Rhabdomyolysis (frequency unknown): Since rhabdomyolysis may occur, if hyperkalemia, myoglobinuria, significant elevation of muscle enzymes in serum, muscle pain, etc. are recognized, administration should be discontinued and appropriate measures should be taken.
⑥ QT prolongation, ventricular tachycardia (including torsade de pointes), ventricular fibrillation (frequency unknown): QT prolongation, ventricular tachycardia (including torsade de pointes), and ventricular fibrillation may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if abnormalities are recognized. It is especially likely to appear in patients with heart disease (myocardial infarction, valvular disease, cardiomyopathy, etc.), so pay attention to the patient's condition after administration.
⑦ Impairment of consciousness, convulsions (frequency unknown): Impairment of consciousness and generalized nervous system (rigidity, myoclonus, myoclonus) may occur, so observe thoroughly and if abnormalities are recognized, take appropriate measures, such as discontinuing administration. In particular, be careful because it is likely to occur in patients with renal dysfunction.
⑧ Interstitial nephritis, acute renal failure (frequency unknown): Interstitial nephritis and acute renal failure may occur. If fever, rash, or abnormal renal function test values (elevated BUN, creatinine, etc.) are recognized as early symptoms, immediately stop administration and take appropriate measures.
⑨ Interstitial pneumonia (frequency unknown): Interstitial pneumonia accompanied by high fever, cough, difficulty breathing, and abnormal chest
⑩ Impaired contraction (less than 0.1%): There are reports that dysfunctional contraction occurs with other H₂ receptor antagonists.
2) Other
*Table: Refer to manual
4. General precautions
1) During treatment, carefully observe the progress and use the minimum amount necessary for treatment depending on the symptoms. If this drug is not effective, change to another treatment. Also, pay attention to blood status, liver function, and renal function.
2) This drug disintegrates in the mouth, but is not absorbed by the oral mucosa, so it is swallowed with saliva or water.
3) If this drug and phosphate conjugate are used together in hemodialysis patients, there may be a risk of loss of calcium carbonate efficacy.
5. Interaction
*Table: Refer to manual
6. Administration to elderly people
Elderly people should administer this drug cautiously, such as reducing the dose or extending the administration interval (it is mainly excreted by the kidneys, but as many elderly people have reduced renal function, there is a risk that the blood concentration may be maintained.)
7. Administration to pregnant and lactating women
1) Administration to pregnant women
It should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks (the safety of administration during pregnancy has not been established).
2) Administration to nursing mothers
Since transfer to breast milk has been reported, breastfeeding mothers should discontinue breastfeeding.
8. Administration to children
Safety for children has not been established (there is little experience with use).
9. Pharmaceutical equivalence test information note 1
A. The test drug pararidine tablets 20 mg (famotidine) (Genupharma Co., Ltd.) and the reference drug Dong-A Gaster tablets 20 mg (Dong-A ST Co., Ltd.) were administered to healthy adults in a single dose orally on an empty stomach in a 2 The 90% confidence interval was within log 0.8 to log 1.25, proving biological equivalence.
*Table: Refer to manual
Note 1 This drug uses the same raw materials as Genu Pharma Co., Ltd. Pararidine Tablet 20 mg (famotidine) and the entire process was manufactured by Genu Pharma Co., Ltd. using the same manufacturing method.
10. Other
Since the symptoms of stomach cancer may be masked by the administration of this drug, it should be administered after confirming that it is not malignant.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 300 tablets/bottle
7. Period of use
36 months from date of manufacture
- Active ingredient: Famotidine (KP) --- 20mg
- Additives (tar color aluminum lake): Blue No. 1, Yellow No. 203
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: Microcrystalline cellulose, magnesium stearate, corn starch, calcium hydrogen phosphate hydrate, sodium starch glycolate, purified water, Tabshield Green (91G941)
2. Effectiveness
1. Main effect
Gastric/duodenal ulcer, anastomotic ulcer, upper digestive tract bleeding (due to peptic ulcer, acute stress ulcer, hemorrhagic gastritis), reflux esophagitis, Zollinger-Ellison syndrome,
Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) of the following diseases: acute gastritis, acute exacerbation of chronic gastritis
3. Dosage and dosage
1. Gastric/duodenal ulcer, anastomotic ulcer, upper digestive tract bleeding (due to peptic ulcer, acute stress ulcer, bleeding ulcer), reflux esophagitis, Zollinger-Ellison syndrome
Adults: As famotidine, take 20 mg orally twice a day (after breakfast, dinner, or at bedtime) or 40 mg once a day (at bedtime).
In the case of upper digestive tract bleeding, treatment is usually initiated with injections and then switched to oral administration after oral administration becomes possible.
2. Improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) of the following diseases: acute gastritis, acute exacerbation of chronic gastritis
Adults: As famotidine, take 10 mg orally twice a day (after breakfast, dinner, or at bedtime) or 20 mg once a day (at bedtime).
Increase or decrease appropriately depending on age and symptoms.
4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to the components of this drug or other H₂ receptor antagonists
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
2. Administer with caution to the following patients.
1) Patients with a history of hypersensitivity to drugs
2) Patients with renal impairment (reduce the dose or use at intervals as blood levels persist)
3) Patients with heart disease (may cause side effects in the cardiovascular system)
4) Patients with liver failure (symptoms may worsen)
5) Elderly people
3. Side effects
1) Serious side effects
① Shock and hypersensitivity (less than 0.1%): Shock and hypersensitivity (anaphylaxis, difficulty breathing, flushing of the body, angioedema (facial edema, pharyngeal edema, etc.), urticaria, etc.) may occur, so observe thoroughly and if abnormalities are recognized, stop administration and take appropriate measures.
② Pancytopenia, agranulocytosis, aplastic anemia, hemolytic anemia (frequency unknown), thrombocytopenia (less than 0.1%): Pancytopenia, agranulocytosis, aplastic anemia, hemolytic anemia, and thrombocytopenia (early symptoms include general malaise, asthenia, subcutaneous and submucosal hemorrhage, fever, etc.) may occur, so conduct blood tests regularly, and if abnormalities are recognized, Stop administration and take appropriate measures.
③ Stevens-Johnson syndrome (cutaneous mucous membrane ocular syndrome), Riell syndrome (toxic epidermal necrolysis) (frequency unknown): Stevens-Johnson syndrome (cutaneous mucous membrane ocular syndrome) and Riel syndrome (toxic epidermal necrolysis) may occur, so observe thoroughly. If these symptoms appear, stop administration and take appropriate measures.
④ Liver dysfunction, jaundice (frequency unknown): Increases in AST (GOT), ALT (GPT), etc. and jaundice may occur, so observe thoroughly, and if abnormalities are recognized, stop administration and take appropriate measures.
⑤ Rhabdomyolysis (frequency unknown): Since rhabdomyolysis may occur, if hyperkalemia, myoglobinuria, significant elevation of muscle enzymes in serum, muscle pain, etc. are recognized, administration should be discontinued and appropriate measures should be taken.
⑥ QT prolongation, ventricular tachycardia (including torsade de pointes), ventricular fibrillation (frequency unknown): QT prolongation, ventricular tachycardia (including torsade de pointes), and ventricular fibrillation may occur, so observe thoroughly and take appropriate measures, such as discontinuing administration if abnormalities are recognized. It is especially likely to appear in patients with heart disease (myocardial infarction, valvular disease, cardiomyopathy, etc.), so pay attention to the patient's condition after administration.
⑦ Impairment of consciousness, convulsions (frequency unknown): Impairment of consciousness and generalized nervous system (rigidity, myoclonus, myoclonus) may occur, so observe thoroughly and if abnormalities are recognized, take appropriate measures, such as discontinuing administration. In particular, be careful because it is likely to occur in patients with renal dysfunction.
⑧ Interstitial nephritis, acute renal failure (frequency unknown): Interstitial nephritis and acute renal failure may occur. If fever, rash, or abnormal renal function test values (elevated BUN, creatinine, etc.) are recognized as early symptoms, immediately stop administration and take appropriate measures.
⑨ Interstitial pneumonia (frequency unknown): Interstitial pneumonia accompanied by high fever, cough, difficulty breathing, and abnormal chest
⑩ Impaired contraction (less than 0.1%): There are reports that dysfunctional contraction occurs with other H₂ receptor antagonists.
2) Other
*Table: Refer to manual
4. General precautions
1) During treatment, carefully observe the progress and use the minimum amount necessary for treatment depending on the symptoms. If this drug is not effective, change to another treatment. Also, pay attention to blood status, liver function, and renal function.
2) This drug disintegrates in the mouth, but is not absorbed by the oral mucosa, so it is swallowed with saliva or water.
3) If this drug and phosphate conjugate are used together in hemodialysis patients, there may be a risk of loss of calcium carbonate efficacy.
5. Interaction
*Table: Refer to manual
6. Administration to elderly people
Elderly people should administer this drug cautiously, such as reducing the dose or extending the administration interval (it is mainly excreted by the kidneys, but as many elderly people have reduced renal function, there is a risk that the blood concentration may be maintained.)
7. Administration to pregnant and lactating women
1) Administration to pregnant women
It should be administered to pregnant women or women who may be pregnant only when the therapeutic benefits are judged to outweigh the risks (the safety of administration during pregnancy has not been established).
2) Administration to nursing mothers
Since transfer to breast milk has been reported, breastfeeding mothers should discontinue breastfeeding.
8. Administration to children
Safety for children has not been established (there is little experience with use).
9. Pharmaceutical equivalence test information note 1
A. The test drug pararidine tablets 20 mg (famotidine) (Genupharma Co., Ltd.) and the reference drug Dong-A Gaster tablets 20 mg (Dong-A ST Co., Ltd.) were administered to healthy adults in a single dose orally on an empty stomach in a 2 The 90% confidence interval was within log 0.8 to log 1.25, proving biological equivalence.
*Table: Refer to manual
Note 1 This drug uses the same raw materials as Genu Pharma Co., Ltd. Pararidine Tablet 20 mg (famotidine) and the entire process was manufactured by Genu Pharma Co., Ltd. using the same manufacturing method.
10. Other
Since the symptoms of stomach cancer may be masked by the administration of this drug, it should be administered after confirming that it is not malignant.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 300 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 2items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 2 | KD Fanitine Tab. 20mg | Precautions for use | 2024.11.07 | PDF[Integrated] 0054_201907803_Precautions for use_Kyungdong Panitin tablets 20 mg.pdf |
| 1 | KD Fanitine Tab. 20mg | Precautions for use | 2023.01.25 | PDFKyungdong Panitin Tablets 20mg_Precautions for use (including change comparison table).pdf |